Dublin-headquartered Jazz Pharmaceuticals said to explore options including sale

Jazz Pharma has developed treatments for sleep disorders and epilepsy and has also worked on cancer medication

Shares of Jazz Pharma have fallen 17% in New York trading this year, giving the company a market value of about $8.3bn.

Jazz Pharmaceuticals Plc is exploring strategic options including a potential sale, people with knowledge of the matter said.

The company is speaking with advisers to help field interest, said the people, who asked not to be identified as the information is private. Jazz Pharma is also studying possibilities that might include a breakup or divestment of parts of the business, the people said.